Ravitz Foundation Phase 1 / Translational Research Center
Enhancing our commitment to advancing cancer treatment
The Ravitz Foundation Translational Research Center enhances the commitment of the University of Michigan Rogel Cancer Center to advance cancer treatment through:
- A dedicated resource for evaluating novel cancer therapies at the earliest stage in the FDA's regulatory process
- Helping to speed these promising therapies from the laboratory to the clinic - where our patients may ultimately benefit
Ravitz Foundation Translational Research Center Focus on Phase I Clinical Trials
Our dedicated translational research is open to clinical trials for all types of cancer. Patients who volunteer to participate in Phase 1 clinical trials are able to participate in these trials in a centralized space with strict monitoring by faculty physicians, research nurses and data managers - all dedicated specifically to the center. The Phase 1 Unit, which is located on the cancer center's second floor, offers five chairs and one bed for infusion as well as facilities for specialized patient monitoring.
Leadership Strength Supports Collaborative Environment
Under the leadership of Rashmi Chugh, M.D., medical director of the Ravitz Foundation Translational Research Center, we offer comprehensive translational research resources for a range of investigators:
- University of Michigan Rogel Cancer Center faculty
- Investigators at other academic institutions
- Pharmaceutical and biotechnology companies
True to the collaborative environment fostered at the University of Michigan and supported by leadership, the Ravitz Foundation Translational Research Center bring clinicians and researchers together in one space, with a laboratory equipped to provide a wide spectrum of services to assess the biological impact of potential therapies used in the clinic.
Improved Efficiencies of Regulatory and Contractual Processes
As an added benefit to the collaborative environment at the Ravitz Foundation Translational Research Center, streamlined regulatory and contractual processes occur. When an investigator initiates a new study with the center, the protocol review process is handled at the same time as study contract services negotiations. This process, much of which is handled electronically, can be efficiently completed in about two months.